【摘要】 目的评价表皮生长因子受体(EGFR)突变的老年局部晚期肺腺癌行三维适形放疗(3DCRT)联合表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗的近期疗效和安全性。方法 26例EGFR突变的老年局部晚期肺腺癌患者接受3DCRT联合EGFR-TKI(吉非替尼或厄洛替尼)治疗。结果全组26例EGFR突变的老年局部晚期肺腺癌患者的有效率88.5%,疾病控制率96.2%,中位生存期32.9个月,中位无进展生存期18.7个月,1、2 a生存率分别为95.0%、72.0%。主要毒副反应为放射性肺炎、放射性食管炎、皮疹和骨髓抑制,所有毒副反应经相应处理后均未影响治疗的顺利进行。结论 3DCRT联合EGFR-TKI治疗EGFR突变的老年局部晚期肺腺癌疗效好,且毒副反应均可耐受。更多还原

【Abstract】 Objective To evaluate the short term efficacy and safety of three dimensional conformal radiation therapy( 3DCRT) combined with epidermal growth factor receptor tyrosine kinase inhibitor( EGFR-TKI) in the treatment of elderly patients with epidermal growth factor receptor( EGFR) mutant type locally advanced lung adenocarcinoma. Methods Twenty-six elderly patients with EGFR mutant type locally advanced lung adenocarcinoma received 3DCRT combined with EGFR-TKI( gefitinib or erlotinib). Results Of the 26 elderly patients with EGFR mutant type locally advanced lung adenocarcinoma,the response rate was 88. 5%,the disease control rate was 96. 2%,the median survival time was 32. 9 months,the median progression free survival time was 18. 7 months,the 1- and 2-year survival rate 95. 0% and 72. 0%. The main toxicities were the radiation pneumonitis,radiation esophagitis,skin rash and marrow depression,and could be recovered by symptomatic treatments. Conclusion 3DCRT combined with EGFR-TKI is effective and safe for elderly patients with EGFR mutant type locally advanced lung adenocarcinoma.更多还原